Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease.
Neurobiol Aging. 2013 Jan;34(1):35-61. doi: 10.1016/j.neurobiolaging.2012.07.018. Epub 2012 Aug 24.
Neurobiol Aging. 2013.
PMID: 22926166
Review.
Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies.
Bartus RT, Kordower JH, Johnson EM Jr, Brown L, Kruegel BR, Chu Y, Baumann TL, Lang AE, Olanow CW, Herzog CD.
Bartus RT, et al. Among authors: kruegel br.
Neurobiol Dis. 2015 Jun;78:162-71. doi: 10.1016/j.nbd.2015.03.023. Epub 2015 Apr 2.
Neurobiol Dis. 2015.
PMID: 25841760
Item in Clipboard
Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
Herzog CD, Brown L, Kruegel BR, Wilson A, Tansey MG, Gage FH, Johnson EM Jr, Bartus RT.
Herzog CD, et al. Among authors: kruegel br.
Neurobiol Dis. 2013 Oct;58:38-48. doi: 10.1016/j.nbd.2013.04.011. Epub 2013 Apr 28.
Neurobiol Dis. 2013.
PMID: 23631873
Item in Clipboard
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, Bolton A, Printz M, Gasmi M, Bishop KM, Kordower JH, Bartus RT.
Herzog CD, et al.
Neurosurgery. 2009 Apr;64(4):602-12; discussion 612-3. doi: 10.1227/01.NEU.0000340682.06068.01.
Neurosurgery. 2009.
PMID: 19349823
Item in Clipboard
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, Johnson EM Jr, Kordower JH, Herzog CD.
Bartus RT, et al.
Neurobiol Dis. 2011 Oct;44(1):38-52. doi: 10.1016/j.nbd.2011.05.026. Epub 2011 Jun 17.
Neurobiol Dis. 2011.
PMID: 21704161
Item in Clipboard
Cite
Cite